Pharmaceutical Biotechnology

About Conference

The Organizing Committee warmly invites scientists, researchers, industry professionals, and academic leaders to participate in the “30^th Annual Meeting on Pharmaceutical Biotechnology”, scheduled for May 21–22, 2026, in London, UK.

This prestigious international forum will bring together experts from biotechnology, pharmaceutical sciences, drug development, and regulatory affairs to explore the latest advancements shaping the future of therapeutic innovation. The meeting will offer a dynamic environment for sharing cutting-edge research, discussing emerging technologies, and addressing key challenges within the pharmaceutical biotechnology landscape.

Conference Features

• Plenary and Keynote Lectures delivered by distinguished global leaders
• Scientific Sessions highlighting breakthroughs in biopharmaceuticals, vaccines, gene therapy, biosimilars, and drug delivery systems
• Poster and Oral Presentations showcasing innovative research contributions
• Young Investigators Forum dedicated to supporting early-career researchers
• Industry Exhibitions presenting advanced tools, platforms, and biotechnological solutions

Why Attend?

• Gain insights into the latest trends and innovations in pharmaceutical biotechnology
• Present your work to a global audience and receive expert feedback
• Build meaningful collaborations with researchers, industry representatives, and policymakers
• Explore new opportunities for professional development, partnerships, and research funding

The primary mission of this annual meeting is to bring together a multidisciplinary community of scientists, biotechnologists, and industry specialists to exchange knowledge, foster innovation, and drive progress in the biopharmaceutical sector.

This event is proudly organized by Conference Series LLC Ltd, a global leader in academic and scientific events, hosting more than 3,000 conferences, workshops, and symposiums each year across the USA, Europe, and Asia, in collaboration with over 1,000 scientific associations.

Benefits of Participation

• Build strong strategic business and academic connections
• Gain cutting-edge insights into advancements in pharmaceutical biotechnology
• Collaborate with pioneers and leaders driving innovation in biopharma, drug delivery, and therapeutic development
• Participate in high-value networking sessions
• Engage in strategy-focused discussions with experts from industry and academia
• Explore specialty exhibit zones featuring the latest biotechnological tools, instruments, and solutions
• Experience the collective energy and focus of like-minded biotech professionals
• Take advantage of spontaneous learning opportunities through interactive workshops
• Join fast-paced Lightning Sessions highlighting breakthrough ideas and emerging technologies
• Witness new product launches and biotech market innovations

Reach a targeted audience of decision-makers, researchers, and industry stakeholders

Target Audience:

• Directors, Presidents, Vice Presidents, Deans, and Heads of Departments
• Pharmaceutical Biotechnology Researchers, Scientists, Faculty, and Students
• Pharma & Biotech Associations and Societies
• Colleges and Research Universities
• Biopharmaceutical Companies and Drug Development Industries
• Medical Device & Diagnostic Manufacturers
• Laboratory Technicians and Research Assistants
• Biotech Entrepreneurs, Start-ups, and Industrial Leaders
• Training & Skill Development Institutes
• Bioinformatics, Software Development, and Data Analytics Companies
• Young Researchers Forum – Young Scientist Benefits
• Young Researcher Awards at the 30th Annual Meeting on Pharmaceutical Biotechnology
• Recognition for outstanding Master’s, Ph.D., or Post-Doctoral research presentations.

Benefits for Young Scientists:

• Premier platform to showcase your research through oral presentations
• Opportunity to share ideas with leading biotech researchers, scientists, and mentors
• Award recognition certificate and memento for selected winners
• Access to timely information, guidance, and feedback through dedicated sessions
• A collaborative environment to build networks and partnerships with fellow young researchers
• Motivation to reach higher research potential and contribute significantly to the field

Session / Tracks

Track 1: Innovations in Drug Discovery & Molecular Design

This track explores cutting-edge strategies driving the next generation of therapeutic discovery. Experts will present breakthroughs in rational drug design, advanced computational modeling, AI-enabled screening, and predictive analytics. Attendees will learn how multi-omics integration, SAR analysis, and fragment-based discovery are accelerating hit-to-lead optimization. Real-world case studies from leading biotech organizations will demonstrate how digital tools are reducing development timelines and enabling more precise target validation. Interactive discussions will support collaboration on early-stage innovation from concept to candidate selection.

Track 2: Pharmaceutical Biotechnology & Next-Gen Biologics

This session highlights the transformative role of biotechnology in modern therapeutics. Discussions will cover recombinant proteins, monoclonal antibodies, gene therapies, and novel biologic platforms. Experts will provide insights into state-of-the-art manufacturing, cell expression systems, purification technologies, and formulation advancements. Attendees will also explore the expanding role of biosimilars and the technologies shaping their global adoption. Dedicated sessions on cell and gene therapy will address clinical progress, scalability challenges, and regulatory considerations, emphasizing the bright future of biopharmaceutical innovation.

Track 3: Breakthrough Therapeutics & Life-Saving Bio-Drugs

Focusing on high-impact medicines, this track examines therapeutic breakthroughs across oncology, infectious diseases, rare disorders, and immunology. Presentations will highlight successful models for identifying unmet medical needs and advancing life-saving interventions. Discussions on pandemic preparedness, global health partnerships, and equitable access will emphasize the ethical responsibility of biotech stakeholders. Participants will gain insights into orphan drug development, accelerated pathways, and strategies to ensure life-changing therapies reach patients worldwide.

Track 4: Clinical Trials, Biotech Regulations & Global Compliance

This track provides a comprehensive overview of regulatory science in the era of biotechnology. Experts will explore innovations in clinical trial design including decentralized, adaptive, and real-world evidence–based models. Sessions will address multi-regional approvals, CTA submissions, GMP/GLP compliance, and post-marketing surveillance. Thought leaders will share strategies to enhance trial diversity, patient engagement, and regulatory navigation. Participants will leave equipped with practical tools for ensuring quality, ethics, and global regulatory alignment.

Track 5: Personalized & Precision Biotherapeutics

This session examines how genomic insights and biomarker-driven approaches are reshaping individualized medicine. Case studies from oncology, immunology, and rare diseases will demonstrate the growing impact of companion diagnostics, pharmacogenomics, and CRISPR-based technologies. Discussions will also address challenges related to data stewardship, cost barriers, and equitable access. Attendees will gain a deeper understanding of how precision strategies are redefining therapeutic outcomes and patient care.

Track 6: Nanobiotechnology & Targeted Drug Delivery

Nanotechnology is revolutionizing targeted therapeutics. This track showcases advancements in nanoparticles, liposomes, polymeric carriers, and nano-enabled delivery systems. Experts will discuss applications in oncology, neurology, infectious diseases, and regenerative medicine, highlighting enhanced bioavailability and targeted precision. Topics include toxicity profiling, regulatory approval, large-scale manufacturing, and next-generation smart materials. Participants will gain a comprehensive view of nanobiotechnology’s potential to transform drug delivery.

Track 7: AI, Machine Learning & Big Data in Biopharma

This session highlights the growing integration of AI and big data across biotech R&D. Topics include predictive analytics for molecular design, automated screening, clinical trial optimization, and real-time pharmacovigilance. Experts will explore digital twins, NLP-powered literature mining, and advanced simulation tools. Key challenges including algorithmic bias, data governance, and interpretability will be addressed. Attendees will discover actionable strategies to incorporate AI into biotech workflows to enhance precision and efficiency.

Track 8: Vaccine Technologies & Immunotherapeutics

Focusing on the latest advances in immune-based therapies, this track explores mRNA vaccines, viral vectors, protein-based platforms, CAR-T cells, and immune checkpoint modulators. Topics include antigen design, immune optimization, delivery systems, and overcoming therapeutic resistance. Discussions will address global access, supply chain considerations, and preparedness for emerging infectious threats. Participants will learn from leading researchers shaping the future of immunotherapy and vaccine development.

Track 9: Quality Assurance, GMP & Biotech Manufacturing Excellence

This track emphasizes best practices in maintaining quality and compliance across biotech production. Sessions will cover GMP standards, QbD approaches, PAT tools, data integrity, and validation frameworks. Case studies will analyze common challenges in manufacturing biologics, biosimilars, and complex molecules. Participants will gain actionable insights into mitigating risks, improving process robustness, and ensuring patient safety through world-class quality systems.

Track 10: Natural Bioactives & Phyto-Biopharmaceuticals

This session explores the vast potential of bioactive natural compounds in pharmaceutical biotechnology. Discussions will cover advanced extraction techniques, standardization, biological evaluation, and the transformation of traditional knowledge into evidence-based therapies. Experts will also examine regulatory frameworks, formulation challenges, and commercialization pathways for botanical drugs. Attendees will gain clarity on bridging natural innovation with modern biopharma standards.

Track 11: Drug Repurposing, Biologics Recycling & Rare Diseases

Showcasing innovative strategies to accelerate therapy development, this track focuses on repurposing approved drugs for new therapeutic areas and advancing treatments for rare diseases. Topics include AI-driven repurposing, regulatory incentives, pricing models, and post-marketing requirements. Speakers will highlight the importance of patient advocacy, global partnerships, and collaborative networks that drive innovation for neglected populations.

Track 12: Biopharmaceutical Supply Chain & Cold Chain Management

This session examines the complex logistics behind delivering biologics and temperature-sensitive therapeutics. Topics include API sourcing, serialization, GDP compliance, cold chain systems, anti-counterfeiting technologies, and blockchain-enabled traceability. Experts will share insights into risk mitigation, regulatory expectations, and digital transformation strategies for a resilient global supply chain.

Track 13: Biosimilars, Biobetters & Regulatory Science

This track offers a deep dive into the scientific, regulatory, and commercial framework surrounding biosimilars and biobetters. Presentations will cover analytical similarity, immunogenicity assessment, comparability studies, and global regulatory pathways. Discussions will include market adoption challenges, pricing pressures, and strategic opportunities in developing next-generation biologics with improved clinical performance.

Track 14: Anti-Microbial Resistance & Infectious Disease Biotechnology

This session examines advanced solutions addressing the global antimicrobial crisis. Topics include novel antibiotics, phage therapy, antimicrobial peptides, host-directed therapies, and microbiome modulation. Policy discussions will address stewardship programs, incentives for antibiotic innovation, and global initiatives to combat resistance. Attendees will gain a comprehensive understanding of emerging biotech strategies for infectious disease control.

Track 15: Pharmacovigilance & Biologic Drug Safety

A critical track dedicated to ensuring post-market safety of biologics. Experts will cover signal detection, AI-enabled safety analytics, global PV regulations, and risk–benefit evaluation. Discussions will highlight challenges in managing biologic adverse events, multi-country reporting, and QPPV responsibilities. Case studies will illustrate how proactive PV systems enhance patient trust and therapeutic reliability.

Track 16: Emerging Biotech Technologies & Future Pharma

This forward-looking track explores pioneering technologies such as 3D-printed biologics, wearable biosensors, synthetic biology, robotics in bioprocessing, bioelectronics, and quantum-assisted modeling. Speakers will discuss regulatory foresight, ethical considerations, and the disruptive potential of these technologies. Attendees will gain early insight into innovations that will define the future of pharmaceutical biotechnology.

Track 17: Pediatric & Geriatric Biopharmacology

This session focuses on age-specific therapeutic challenges and opportunities. Topics include tailored pharmacokinetics, innovative dosage forms for children and seniors, ethical considerations in clinical trials, and age-adapted regulatory pathways. Case studies will highlight therapeutic innovations for chronic, neurodegenerative, and rare pediatric diseases.

Track 18: Biopharmaceutical Formulation & Delivery Systems

This track highlights advanced formulation strategies—from traditional dosage forms to sophisticated delivery technologies. Topics include amorphous dispersions, hot-melt extrusion, targeted delivery systems, and patient-centric formulation design. Regulatory aspects related to bioequivalence and scale-up will also be addressed, offering practical guidance for formulation scientists and developers.

Track 19: Global Health Policy, Ethics & Access to Biotherapeutics

This session explores the ethical, economic, and policy dimensions of global access to medicines. Topics include intellectual property, tiered pricing, regulatory harmonization, humanitarian access, and the role of generic biologics. Discussions will emphasize the importance of transparency, equity, and public–private partnerships in expanding access to life-saving biotherapies.

Track 20: Career Pathways, Leadership & Innovation in Biotechnology

This track is designed to guide professionals at every stage of their biotech journey. Sessions cover career advancement strategies, scientific communication, leadership development, and emerging roles in digital health and regulatory science. Entrepreneurs will share insights on funding, IP strategy, and biotech innovation ecosystems. Career clinics and mentorship programs will support skill development and networking.

Accreditation

All major Conference Series Conferences are accredited with Continuing Education (CE), Continuing Professional Development (CPD) and Continuing Medical Education (CME) credits respectively.

CME Credits:

Continuing Medical Education (CME) helps medical professionals maintain their competence and stay updated on new developments in their field. Conference Series events are recognized and accredited with CME credits, supporting participants in enhancing their skills and professional growth. Physicians require a set number of CME credits each year to maintain their medical licenses, with credits authorized by the Accreditation Council for Continuing Medical Education. Attending CME-accredited conferences provides valuable opportunities to learn about the latest technologies, treatments, and advancements, while speaking at these events allows clinicians to share expertise and strengthen their professional reputation.

CE Credits:

Continuing Education (CE) credits help professionals maintain their licenses and stay updated in their fields. Conference Series conferences offer ample opportunities to earn CE credits, which can enhance career prospects, open new job opportunities, and support lifelong learning. CE typically includes college courses or vocational training for working professionals and holds significant value in medical, clinical, and research sectors even after formal degrees are completed. Attending CE conferences helps professionals stay current with advancements, expand their networks, and build connections that may lead to future opportunities. CE also benefits employers by aiding recruitment and supports licensing bodies and professional organizations in maintaining high standards of practice.

CPD Credits:

Continuing Professional Development (CPD) reflects a professional’s ongoing commitment to improving skills and competence throughout their career. It promotes proactive, continuous learning and ensures that accredited courses meet high international standards. CPD helps professionals stay current, fill knowledge gaps, enhance productivity, and build confidence, making it essential for career advancement and credibility. CPD hours can be earned through education, leadership, teaching, major projects, research, and publications. Conference Series conferences are CPD-accredited, supporting the growth and development of research and industry professionals.

Market Outlook

The global biotechnology market is forecast to grow steadily in 2026 at a CAGR of 8–10%, building on its valuation of over $1.3 trillion. Growth is driven by advancements in genomics, synthetic biology, and the increasing integration of AI in drug discovery and genetic engineering. Healthcare biotechnology remains the dominant sector, with biopharmaceuticals accounting for nearly 60% of revenue, supported by innovations in monoclonal antibodies, gene therapies, and mRNA platforms. Agricultural biotechnology continues to expand through CRISPR-based crop development and sustainable biofertilizers, while environmental biotechnology gains momentum with rising adoption of bioplastics and waste management solutions. North America leads the market with strong R&D investment, while Europe and Asia-Pacific experience rapid growth through supportive policies and emerging biotech startups. Overall, 2026 marks a transformative year for biotechnology, driven by growing collaborations between biotech and AI industries and increasing global demand for solutions in healthcare, food security, and environmental sustainability.

Related Society and Association

1. Biotechnology Innovation Organization (BIO)
2. EuropaBio
3. American Society for Microbiology (ASM)
4. Biotechnology Industry Research Assistance Council (BIRAC)
5. BioIndustry Association (BIA) – bioindustry.org
6. BIOTECanada 
7. Japan Bioindustry Association (JBA)
8. European Federation of Biotechnology (EFB)
9. Swiss Biotech Association
10. AusBiotech 

Past Conference Report

Biotechnology 2025

The previous edition of the Biotechnology Congress successfully brought together leading researchers, industry experts, and academic professionals from across the globe to share advancements in genomics, synthetic biology, biopharmaceuticals, agricultural biotechnology, and environmental applications. The conference featured impactful keynote sessions, interactive panel discussions, and high-quality oral and poster presentations that highlighted emerging innovations and real-world biotech solutions. Participants benefited from extensive networking opportunities, collaborative discussions, and knowledge exchange that fostered new partnerships between academia, industry, and research organizations. The event concluded with recognition of outstanding contributions through awards and provided a strong platform for professionals to advance their work, explore new trends, and contribute to the growing global biotechnology community.